Fernando J. Martinez, MD, MS
Gregg Sherman, MD
Chief Medical Officer, NACE
Kilbride Associates Healthcare Communications
San Francisco, CA
Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, NY
Kevin Flaherty, MD, MS
Professor in Pulmonary
and Critical Care Medicine
University of Michigan Health System
Ann Arbor, MI
David J. Lederer, MD, MS
Associate Professor of
Medicine & Epidemiology
Lung Disease Program
Columbia University Medical Center
New York, NY
Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic Director, Pulmonary Hypertension Clinic Head of Alpha-1 Foundation Clinical Resource Center Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Arunabh Talwar, MD, FCCP
Director, Pulmonary Hypertension and Advanced Lung Disease Program
North Shore University Hospital, Manhasset, New York
Professor Of Medicine
Hofstra Northwell School of Medicine
||Idiopathic Pulmonary Fibrosis (IPF): Defining the Role of the Primary Care Clinician in Diagnosis and Therapy
||Nov 01 2017
||Oct 31 2018
||Primary Care Providers
Welcome to the National Association for Continuing Education webcast from the NACE Emerging Challenges in Primary Care 2017 conference.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia. IPF is associated with increased comorbidity, healthcare resource utilization, and direct medical costs. The disease has a poorer prognosis than other interstitial lung diseases, with a median survival of 3 years from diagnosis.
The critical role of the Primary Care Clinician revolves around recognizing patients at risk for IPF, ordering appropriate screening tests like a HRCT, and subsequent referral to specialty centers for evaluation and monitoring. This program incorporates video of real patients with IPF detailing their experiences with the disease and was recorded live with the permission of the presenter.
After completing this program participants should be able to:
- Describe the typical clinical presentation of a patient with possible idiopathic pulmonary fibrosis (IPF).
- Discuss the diagnostic approach to a patient with suspected IPF.
- Discuss and contrast the available pharmacotherapeutic options for patients with IPF.
- Discuss and contrast the available nonpharmacotherapeutic options for patients with IPF.
How To Obtain Your CME Certificate
- Register for the course at www.naceonline.com.
- View the content.
- Complete and submit the post-test and evaluation.
- A minimum passing score of 80% must be earned on the post-test in order to complete the CME
- Print your CME certificate.
National Association for Continuing Education
|Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.25 contact hours of continuing education (which includes 0.25 pharmacology hours).
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.
Kevin Flaherty, MD, MS serves as a consultant for Boehringer Ingleheim and Genentech. Dr. Flaherty also serves on the advisory board for Fibrogen.
David J. Lederer, MD, MS serves on the scientific advisory board committee for Boehringer-Ingelheim, Genentech, Global Blood Therapeautics, Roche, Fibrogen, Veracyte, Patara, and Philips Repsironics.
Fernando Martinez, MD, MS serves on the steering committee for Afferent, AstraZeneca, Bayer, Boehringer-Ingelheim, Gilead, GSK, and Veracytes. Dr. Martinez also serves on the advisory board for Adept, AZ, BI, ProTerrix Bio, Concert, Genentech, GSK, Novartis, Patara, Pearl, and Theravance. Dr. Martinez has done CME Presentations and served as a speaker for AZ, BI, Columbia University, GSK, Integritas, Methodist Hospital, Mitler, NYU, NACE, Peer View, Potomac, Prime, and the Puerto Rican Respiratory Society. Additionally, Dr. Martinez has served on the DSMB for Chiesl, UpToDate, WebMD, Biogen, and GSK.
Franck Rahaghi, MD, MHS, FCCP serves as a Consultant/Speaker/Researcher for Boehringer Ingleheim, Gennentech, and Merck.
Arunabh Talwar, MD, FCCP serves as a speaker for Boehringer Ingleheim
Gregg Sherman, MD, Course Director, has no relationships to disclose.
Josh Kilbridge, Medical Writer, has no relationships to disclose.
Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
This educational activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.